Cargando…

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Metabolic sequelae associated with PCOS range from insulin resistance to type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Insulin resistance plays a significant role in the pathophysiology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdalla, Mohammed Altigani, Deshmukh, Harshal, Atkin, Stephen, Sathyapalan, Thozhukat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338645/ https://www.ncbi.nlm.nih.gov/pubmed/32670541 http://dx.doi.org/10.1177/2042018820938305

Ejemplares similares

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2021)

The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2021)

Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2022)

Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice
por: Shah, Najeeb, et al.
Publicado: (2021)

Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity
por: Sathyapalan, Thozhukat, et al.
Publicado: (2010)

Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
por: Alalami, Huda, et al.
Publicado: (2018)

Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome
por: Kahal, Hassan, et al.
Publicado: (2011)

Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Components of the Complement Cascade Differ in Polycystic Ovary Syndrome
por: Butler, Alexandra E., et al.
Publicado: (2022)

ODP141 Complement Activation and Homeostasis Works Primarily Through the Alternative Pathway in Polycystic Ovary Syndrome
por: Atkin, Stephen, et al.
Publicado: (2022)

COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2020)

The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

Pregnancy in polycystic ovary syndrome
por: Kamalanathan, Sadishkumar, et al.
Publicado: (2013)

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome
por: Javed, Zeeshan, et al.
Publicado: (2019)

Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Complement Dysregulation in Obese Versus Nonobese Polycystic Ovary Syndrome Patients
por: Butler, Alexandra E., et al.
Publicado: (2023)

The Association of the Polychlorinated Biphenyl Class of Endocrine Disruptors With Polycystic Ovary Syndrome and Thyroid Dysfunction
por: Brennan, Edwina, et al.
Publicado: (2021)

Salivary testosterone measurement in women with and without polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Salivary and serum androgens with anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2018)

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019)

Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?
por: Moin, Abu Saleh Md, et al.
Publicado: (2020)

Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Inflammatory Markers in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D Metabolites
por: Moin, Abu Saleh Md, et al.
Publicado: (2022)

Serum polychlorinated biphenyl levels and circulating miRNAs in non-obese women with and without polycystic ovary syndrome
por: Brennan, Edwina, et al.
Publicado: (2023)

Oxidative Stress Markers and Heat Shock Proteins in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D
por: Nandakumar, Manjula, et al.
Publicado: (2023)

SAT366 Expression of Amyloid-related Proteins Associated With Dementia in Polycystic Ovary Syndrome Compared to a Control Population
por: Butler, Alexandra E, et al.
Publicado: (2023)

HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study
por: Butler, Alexandra E., et al.
Publicado: (2023)

Exploration of the correlation of serum polychlorinated biphenyl levels with luteal phase hormonal parameters and infertility in women with or without polycystic ovary syndrome
por: Butler, Alexandra E., et al.
Publicado: (2023)

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020)

Classical and alternate complement factor overexpression in non-obese weight matched women with polycystic ovary syndrome does not correlate with vitamin D
por: Moin, Abu Saleh Md, et al.
Publicado: (2022)

High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome
por: Butler, Alexandra E., et al.
Publicado: (2023)

Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome
por: Cho, Li-Wei, et al.
Publicado: (2017)

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
por: Dawson, Alison J., et al.
Publicado: (2017)

Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations
por: Butler, Alexandra E., et al.
Publicado: (2020)

Effect of Moderate Aerobic Exercise on Complement Activation Pathways in Polycystic Ovary Syndrome Women
por: Ramanjaneya, Manjunath, et al.
Publicado: (2022)

The Effect of a Very-Low-Calorie Diet (VLCD) vs. a Moderate Energy Deficit Diet in Obese Women with Polycystic Ovary Syndrome (PCOS)—A Randomised Controlled Trial
por: Deshmukh, Harshal, et al.
Publicado: (2023)

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects
por: Al-Qaissi, Ahmed, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9a94o2unn043i4su7im1tlt66m